2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Monday, September 23, 2019

1:45pm-3:15pm: Potential treatment considerations for refractory REM behavior disorder

J. Nguyen, K. Papesh (Las Vegas, NV, USA)

Functional (Psychogenic) Movement Disorders · Les Muses Terrace, Level 3

1:45pm-3:15pm: Practice Patterns with Onabotulinum Toxin-A for Movement disorders: South Asian Neurologist Survey

G. Kumar, P. Wadia, H. Kumar, P. K, S. Gupta, V. Goyal, A. Raza, A. Zuzek, A. Patel (Bengaluru, India)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Pre-diagnosis physical activity habits are associated with age of diagnosis and postural instability in Parkinson’s disease

M. Landers, K. Johnson, S. Johnson, J. Lyle, T. Ormsby, D. Salgo, J. Zorn, A. Murtishaw, A. Salazar, J. Kinney (Las Vegas, NV, USA)

Physical and Occupational Therapy · Les Muses Terrace, Level 3

1:45pm-3:15pm: Pre-Dopa DBS: is early deep brain stimulation able to modify the natural course of Parkinson’s disease?

M. Porta, D. Servello, AR. Bona, E. Zekaj, G. Gonzalez-Escamilla, G. Groppa (Milan, Italy)

Quality of Life · Les Muses Terrace, Level 3

1:45pm-3:15pm: PRECISE-PD: From pathophysiology to precision medicine for Parkinson’s disease

JC. Corvol, S. Durrleman, S. Lehericy, D. Devos, W. Meissner, E. Bezard, D. Grosset, H. Morris, O. Monchy, EA. Fon, F. Durif, F. Tubach, Y. de Rycke, O. Rascol (Paris, France)

Genetics · Les Muses Terrace, Level 3

1:45pm-3:15pm: Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease

K. Satterly, G. Davies, B. Gajera, J. Wright, H. Lin, S. Muppaneni, K. To, S. Shrewsbury, J. Hoekman (Seattle, WA, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Preclinical efficacy of drugs identified by IBM-Watson for repurposing to treat L-DOPA-induced dyskinesia

N. Visanji, A. Lacoste, P. Ravenscroft, S. Spangler, S. Fox, A. Lang, J. Brotchie, T. Johnston (Toronto, ON, Canada)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia

K. Svensson, J. Beck, J. Hao, J. Schaus, X. Wang, B. Heinz, S. Mitchell, K. Wafford, C. Yang, L. Zhang, S. Castner, G. Williams, H. Marston, R. Bruns (Indianapolis, IN, USA)

Neuropharmacology · Les Muses Terrace, Level 3

1:45pm-3:15pm: Predicting Impulse Control Disorders in Parkinson’s Disease: A Challenging Task

J. Faouzi, S. Bekadar, O. Colliot, JC. Corvol (Paris, France)

Psychiatric Manifestations · Les Muses Terrace, Level 3

1:45pm-3:15pm: Predictive Factors for Depression in a Multicentric Parkinson’s Disease Mexican Cohort

A. Banegas-Lagos, A. Cervantes-Arriaga, D. Garza-Brambila, E. Garcia-Berlanga, K. Salinas-Barboza, S. Isais-Millan, A. Anaya-Escamilla, E. Velazquez-Avila, G. Parra, A. Gonzalez-Cantú, M. Rodriguez-Violante, D. Martinez-Ramirez (Monterrey, Mexico)

Psychiatric Manifestations · Les Muses Terrace, Level 3